Literature DB >> 14711162

Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.

Carol A Westall1, Rita Nobile, Sharon Morong, J Raymond Buncic, William J Logan, Carole M Panton.   

Abstract

Electroretinograms (ERGs) have been recorded longitudinally in children before and during treatment with the antiepileptic drug vigabatrin for the past 3.5 years. Vigabatrin induced changes in ERG responses occur in children; the most dramatic changes occur in the oscillatory potentials. The purpose of this study was to identify changes in ERG responses associated with discontinuation of vigabatrin treatment. If vigabatrin-induced changes reverse after discontinuation of the drug we infer that the original change is not an indicator of toxicity. ERG data were analyzed from 17 children who discontinued vigabatrin therapy. The duration of treatment ranged from 5 to 52 months, the age for the first ERG ranged from 6 to 38 months (median 10 months). ERGs were tested using the standard protocol established by the International Society for Clinical Electrophysiology of Vision, with Burian-Allen bipolar contact-lens electrodes. In addition to standard responses we recorded photopic oscillatory potentials (OPs). During vigabatrin treatment OPs show a greater change than other ERG responses, with the early occurring wavelets from the photopic OPs showing the greatest change. With discontinuation of vigabatrin the amplitude of the early wavelets of the photopic OPs increased dramatically compared with amplitudes while taking the drug (paired t-test, p = 0.000075). The scotopic oscillatory potentials also show some recovery. Although changes in oscillatory potentials may occur with vigabatrin toxicity, a large change likely occurs with a non-toxic pharmacological effect of vigabatrin on GABAergic amacrine cells in the inner plexiform layer. Reduction of OPs in children on vigabatrin may not be related to toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711162      PMCID: PMC3880365          DOI: 10.1023/b:doop.0000005339.23258.8f

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  42 in total

1.  Vigabatrin and retinal changes.

Authors:  Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

2.  Visual field constriction and electrophysiological changes associated with vigabatrin.

Authors:  Dorothea Besch; Anne Kurtenbach; Eckart Apfelstedt-Sylla; Bettina Sadowski; Dieter Dennig; Christiane Asenbauer; Eberhart Zrenner; Ulrich Schiefer
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

3.  Electro-ophthalmological recovery after withdrawal from vigabatrin.

Authors:  Hellen S Graniewski-Wijnands; Kors van der Torren
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

4.  Visual field and electrophysiological abnormalities due to vigabatrin.

Authors:  Kors van der Torren; Hellen S Graniewski-Wijnands; B C P Polak
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

5.  The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.

Authors:  I F Comaish; C Gorman; G M Brimlow; C Barber; G M Orr; N R Galloway
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

6.  The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin.

Authors:  Carol A Westall; William J Logan; Kim Smith; J Raymond Buncic; Carole M Panton; Mohamed Abdolell
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

Review 7.  Treatment of infantile spasms: an evidence-based approach.

Authors:  Mark Mackay; Shelly Weiss; O Carter Snead
Journal:  Int Rev Neurobiol       Date:  2002       Impact factor: 3.230

8.  Infantile spasms in Down syndrome: good response to a short course of vigabatrin.

Authors:  R Nabbout; I Melki; B Gerbaka; O Dulac; C Akatcherian
Journal:  Epilepsia       Date:  2001-12       Impact factor: 5.864

9.  Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children.

Authors:  G F A Harding; E L Spencer; J M Wild; M Conway; R L Bohn
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

10.  Longitudinal changes in photopic OPs occurring with vigabatrin treatment.

Authors:  Sharon Morong; Carol A Westall; Rita Nobile; J Raymond Buncic; William J Logan; Carole M Panton; Mohamed Abdolell
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

View more
  19 in total

1.  Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.

Authors:  Ulrika Kjellström; Sten Kjellström; Anitha Bruun; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

2.  Epilepsy: Vigabatrin treatment and visual field loss.

Authors:  Catherine Chiron; Olivier Dulac
Journal:  Nat Rev Neurol       Date:  2011-03-01       Impact factor: 42.937

3.  Electroretinographic (ERG) responses in pediatric patients using vigabatrin.

Authors:  Anne Moskowitz; Ronald M Hansen; Susan E Eklund; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

Review 4.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

5.  Reduced visual function associated with infantile spasms in children on vigabatrin therapy.

Authors:  Dena S Hammoudi; Sophia S F Lee; Adena Madison; Giuseppe Mirabella; J Raymond Buncic; William J Logan; O Carter Snead; Carol A Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-02       Impact factor: 4.799

6.  Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.

Authors:  Sivan Durbin; Giuseppe Mirabella; J Raymond Buncic; Carol A Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-11       Impact factor: 4.799

7.  Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.

Authors:  John M Wild; Catherine Chiron; Hyosook Ahn; Michel Baulac; Joseph Bursztyn; Enrico Gandolfo; Ivan Goldberg; Francisco Javier Goñi; Florence Mercier; Jean-Philippe Nordmann; Avinoam B Safran; Ulrich Schiefer; Emilio Perucca
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

8.  Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.

Authors:  J Raymond Buncic; Carol A Westall; Carole M Panton; J Robert Munn; Leslie D MacKeen; William J Logan
Journal:  Ophthalmology       Date:  2004-10       Impact factor: 12.079

9.  Longitudinal changes in photopic OPs occurring with vigabatrin treatment.

Authors:  Sharon Morong; Carol A Westall; Rita Nobile; J Raymond Buncic; William J Logan; Carole M Panton; Mohamed Abdolell
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

10.  Retinal defect in children with infantile spasms of varying etiologies: An observational study.

Authors:  Michelle T McFarlane; Tom Wright; Blathnaid McCoy; O Carter Snead; Carol A Westall
Journal:  Neurology       Date:  2019-12-02       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.